Efficacy Of Methimazole Versus Radioiodine in Patients With Hyperthyroidism: A Meta-analysis Of Randomized Controlled Trials

Résumé

Abstract Background: The efficacy of methimazole compared to radioactive iodine (RAI) therapy for hyperthyroidism remains uncertain. Here, we conducted a meta-analysis to compare methimazole to RAI in the treatment of hyperthyroid patients. Methods: We conducted a meta-analysis including English-randomized clinical trials (RCTs) published before March 5, 2023, to address this issue. The primary outcome was euthyroidism rate, while secondary outcomes included hypothyroidism, relapse, persistent hyperthyroidism, and cure rate. Review Manager software was used for analysis. Results: Six studies were included including 761 patients. The methimazole group had non-significantly higher rates of euthyroidism (RR = 2.09, 95% CI [0.90, 4.87], P = 0.09). The RAI group significantly increased the rates of hypothyroidism (RR = 0.06, 95% CI [0.03, 0.15], P < 0.00001). There were no significant differences in relapse, persistent hyperthyroidism, or cure rates between the two treatments (RR = 1.34, 95% CI [0.31, 5.86], P = 0.70), (RR = 0.4, 95% CI [0.07, 2.13], P = 0.28), and (RR = 0.84, 95% CI [0.58, 1.20], P = 0.34), respectively. Conclusion: Methimazole was not inferior to RAI in curing hyperthyroid patients, with comparable relapse rates. Methimazole is an effective alternative to ablative therapies like RAI with a lower risk of hypothyroidism.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0